<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63848">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02020837</url>
  </required_header>
  <id_info>
    <org_study_id>202676</org_study_id>
    <nct_id>NCT02020837</nct_id>
  </id_info>
  <brief_title>A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema</brief_title>
  <official_title>A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the impact of lymphaticovenous microanastomosis in volume reduction
      of postmastectomy upper extremity lymphedema. We hypothesize that multiple lymphaticovenous
      micro-anastomosis in the distal arm will result in the reduction of volume and improvement
      in quality of life of patients with post-mastectomy lymphedema
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes relative to baseline in the volume of the affected limb at 3 and 6 months from surgery</measure>
    <time_frame>3 and 6 months from surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Lymphedema</condition>
  <condition>Post Mastectomy</condition>
  <arm_group>
    <arm_group_label>Lymphaticovenous Micro-Anastomosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphaticovenous Micro-Anastomosis</intervention_name>
    <arm_group_label>Lymphaticovenous Micro-Anastomosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 18-70 years of age

          -  Subject is Stage II-IV unilateral lymphedema

        Exclusion Criteria:

          -  Subject is less than 6 months from completion of cancer treatment

          -  Subject has allergic reaction to the lymphatic contrast agent (Indocyanine Blue)

          -  Subject is medically unfit for the procedure

          -  Subject is unable to complete the follow-up visits

          -  Women with a positive urine pregnancy test are excluded from this study; women of
             childbearing potential (defined as those who have not undergone a hysterectomy or who
             have not been postmenopausal for at least 24 consecutive months) must agree to
             refrain from breast feeding and practice adequate contraception as specified in the
             informed consent. Adequate contraception consists of oral contraceptive, implantable
             contraceptives, injectable contraceptives, a double barrier method, or abstinence.

          -  Subject has bilateral lymphedema
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mauricio Moreno, MD</last_name>
    <phone>501-686-7009</phone>
    <email>mamoreno@uams.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daisy Wade</last_name>
      <phone>501-686-8274</phone>
      <email>dewade@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Mauricio Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>V. Suzanne Klimberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
